Health care stocks were leaning lower premarket Monday with the Health Care Select Sector SPDR Fund (XLV) declining by 0.1% and the iShares Biotechnology ETF (IBB) down 0.3% recently.

KalVista Pharmaceuticals (KALV) shares were up more than 17% after the company said the US Food and Drug Administration approved its drug Ekterly, which is intended for treating acute attacks of hereditary angioedema in patients aged 12 and above.

Jasper Therapeutics (JSPR) shares were declining by more than 66% after the company said it is shutting down its asthma trial after discovering a faulty batch of its experimental drug was used to treat individuals who were enrolled in a trial evaluating briquilimab.

Lenz Therapeutics (LENZ) shares were up nearly 0.1% after the company and Laboratoires Thea said they signed an exclusive licensing and commercialization agreement to market LNZ100, Lenz's investigational eye drop for presbyopia, in Canada.